



Vaccines and Global Health: The Week in Review
6 June 2020 :: Number 555
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday evening at midnight [0000 GMT-5]. The PDF is posted and the elements of each edition are presented as a set of blog posts at <https://centerforvaccineethicsandpolicy.net>. This blog allows full-text searching of over 9,000 entries.

Comments and suggestions should be directed to

*David R. Curry, MS
Editor and
Executive Director
Center for Vaccine Ethics & Policy
david.r.curry@centerforvaccineethicsandpolicy.org*

Request email delivery of the pdf: If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.

Contents [click on link below to move to associated content]

- A. Milestones :: Perspectives :: Featured Journal Content
- B. [Emergencies](#)
- C. [WHO; CDC \[U.S., Africa, China\]](#)
- D. [Announcements](#)
- E. [Journal Watch](#)
- F. [Media Watch](#)



Milestones :: Perspectives :: Research

:::::
::::

World leaders make historic commitments to provide equal access to vaccines for all

:: The Global Vaccine Summit, hosted by the UK, raises US\$ 8.8 billion from 32 donor governments and 12 foundations, corporations and organisations to immunise 300 million children and support the global fight against COVID-19

:: US\$ 567 million also raised for new innovative financing instrument to provide access to COVID-19 vaccines for low- and middle-income countries

:: Boris Johnson: "Together we rise to fulfil the greatest shared endeavour of our lifetime – the triumph of humanity over disease, now and for the generations that follow."

London, 4 June 2020 – **World leaders have pledged an additional US\$ 8.8 billion for Gavi, the Vaccine Alliance, far exceeding the target of US\$ 7.4 billion.**

The funding will help immunise 300 million more children in the world's poorest countries against diseases like measles, polio and diphtheria by the end of 2025. It will also support health systems to withstand the impact of coronavirus and maintain the infrastructure necessary to roll out a future COVID-19 vaccine on a global scale.

The pledges were made at the [Global Vaccine Summit 2020](#), hosted by UK Prime Minister Boris Johnson. Representatives from 52 countries, including 35 Heads of State, joined leaders from global health organisations, the private sector, vaccine manufacturers and civil society organisations to support the Vaccine Alliance's work protecting almost half the world's children against deadly, preventable infectious diseases..

The UK remains the Vaccine Alliance's largest donor, pledging the equivalent of £330 million per year over the next five years. Other top donors include the Bill & Melinda Gates Foundation, Norway, Germany and the United States. Eight countries made their first ever pledge to Gavi, including Bhutan, Burkina Faso, Cameroon, Finland, Greece, New Zealand, Portugal and Uganda...

...Over the next five years, we will also see the largest investment in immunisation ever made by lower-income countries.

Gavi-supported countries will contribute US\$ 3.6 billion towards the cost of buying vaccines – more than double the amount for the 2016-2020 period and more than 40% of the total estimated cost of supplying vaccines to these countries. They are also expected to invest around US\$ 6 billion in immunisation service delivery costs over the same period. The dire economic effects of the COVID-19 pandemic may, however, disrupt these estimates.

Gavi's market-shaping efforts to make life-saving vaccines more affordable have seen a 21% price reduction for fully immunising a child with pentavalent, pneumococcal and rotavirus vaccines – from \$20.01 in 2015 to \$15.90 in 2018...

...The world's biggest vaccine manufacturers also committed to continue supplying the billions of doses needed to continue increasing vaccine coverage across Africa and Asia. The Vaccine Alliance is one of the world's largest and most successful public-private partnerships, and the wider private sector continued to show support for its mission with the announcement of more than US\$ 70 million of new pledges and partnerships, bringing new technology, networks and expertise to help solve some of global health's most intractable problems.

"On behalf of the countless vaccinators, supply chain workers, programme managers and the many, many others that work tirelessly every day to ensure children in vulnerable countries continue to receive lifesaving vaccines – thank you," said Dr Ngozi Okonjo-Iweala, Gavi Board Chair. "We have made incredible progress over the past two decades improving vaccine coverage and reducing child mortality across Africa and Asia. This funding will give countries new hope that, despite the devastating impact of COVID-19, this progress can be sustained and built on. The Alliance will now get to work making this happen."

The Global Vaccine Summit also saw the launch of the Advance Market Commitment for COVID-19 Vaccines (Covax AMC), a new innovative financing instrument to provide access to COVID-19 vaccines for low- and middle-income countries. This is the first building block towards a global mechanism to ensure equitable access to future COVID-19 vaccines. US\$ 567 million was raised today in initial seed money for the AMC from 12 donors...

:::::

Bill & Melinda Gates Foundation pledges \$1.6 billion to Gavi, the Vaccine Alliance, to protect the next generation with lifesaving vaccines

JUNE 04, 2020

Global leaders unite to safeguard 300 million more children from disease and mitigate consequences of COVID-19

:::::

Gavi launches innovative financing mechanism for access to COVID-19 vaccines

::: *Gavi Advance Market Commitment for COVID-19 Vaccines (Gavi Covax AMC) launched at Global Vaccine Summit 2020 draws strong support, early commitments from global leaders*
::: *New financing mechanism, aimed at supporting affordable access for developing countries, is first building block in broader initiative to create a Covax Facility for global access to eventual COVID-19 vaccines*

::: *Ngozi Okonjo-Iweala: "The Gavi Covax AMC increases the likelihood that when we have a successful vaccine or vaccines, it will be available in sufficient quantities and affordable to developing countries."*

Geneva, 04 June 2020 – Gavi, the Vaccine Alliance today launched the Gavi Advance Market Commitment for COVID-19 Vaccines (Gavi Covax AMC), a new financing instrument aimed at incentivising vaccine manufacturers to produce sufficient quantities of eventual COVID-19 vaccines, and to ensure access for developing countries.

The Gavi Covax AMC is being launched with an initial goal of raising US\$ 2 billion; enough for Gavi-supported countries to immunise health care workers as well as high-risk individuals, and create a flexible buffer of doses to be deployed where needed most.

It will not be a stand-alone financing instrument but rather represents the first building block in broader efforts to develop a COVID-19 Global Vaccine Access Facility (Covax Facility) aimed at ensuring equitable access to COVID-19 vaccines for all countries, at all levels of development, that wish to participate.

The Gavi Covax AMC is inspired by similar mechanisms that have successfully secured equitable global access to pneumococcal and Ebola vaccines. By providing volume guarantees for specific candidates before they are licenced, as well as market-wide guarantees, the Gavi Covax AMC will encourage manufacturers to make investments in production capacity. This in turn increases supply availability and reduces the amount of time it takes for licenced vaccines to become available, particularly to the poorest countries around the world.

"Today's launch moves us one step closer to the essential vision of equitable access for all," said Dr Ngozi Okonjo-Iweala, Chair of the Gavi Board. "By de-risking the cost of investing in high volumes of manufacturing against an unknown outcome – and making sure those investments are made now – the Gavi Covax AMC increases the likelihood that when we have a successful vaccine or vaccines, it will be available in sufficient quantities and affordable to developing countries..."

:::::

HPV vaccine manufacturers commit to provide enough supply to immunize at least 84 million girls in Gavi countries

:: On the eve of the Global Vaccine Summit 2020, five manufacturers commit to increasing and prioritising HPV vaccine supply to Gavi-supported countries, which have among the highest cervical cancer burdens in the world

:: Gavi estimates that up to 84 million girls in the poorest countries could receive HPV vaccines in the next 5-year period, averting 1.4 million future cervical cancer deaths

:: Dr Seth Berkley: "We are extremely grateful to MSD, GSK, Innovax, Serum Institute of India Pvt. Ltd. and Walvax for these commitments, which should have a profound impact on women's lives"

Geneva, 03 June 2020 – Vaccine manufacturers MSD, GSK, Innovax, Serum Institute of India Pvt. Ltd. (SII) and Walvax have pledged to ramp up human papillomavirus (HPV) vaccine supply availability for Gavi-supported countries, ahead of tomorrow's Global Vaccine Summit 2020.

This commitment is part of an ongoing UNICEF-led tender that aims to enable Gavi to dramatically increase its reach from 50 million girls, as initially planned, to 84 million girls during the next five-year period, leading to the prevention of an estimated 1.4 million future deaths from cervical cancer...



WHO welcomes crucial new funding for vaccines

4 June 2020 *News release*

WHO welcomes funding commitments made at today's [Global Vaccine Summit](#), hosted virtually by the UK government. The Summit is Gavi, the Vaccine Alliance's third pledging conference and follows the successful Berlin summit in January 2015.

The new pledges will enable Gavi to protect the next generation and reduce disease inequality by reaching an additional 300 million children with vaccines by 2025.

"Thanks to vaccines, hundreds of millions of deaths have been prevented. Polio has been pushed to the brink of eradication, and just in the past few years new vaccines have become available for Ebola and malaria," said Dr Tedros Adhanom Ghebreyesus, WHO Director-General.

"But vaccines only realize their true power when they are deployed to protect the poorest and most vulnerable. The COVID-19 pandemic is unravelling many of the gains we have made, with vaccination campaigns for polio, cholera, measles, diphtheria, and meningitis."

The bold funding commitments mean that the Gavi Alliance will be better able to maintain immunization in lower-income countries, mitigating the impact of the COVID-19 pandemic. They will also help strengthen health systems.

The backdrop of the COVID-19 pandemic is a sobering reminder of how much individual health depends on collective health and the critical role that vaccines play in keeping the global population safe and healthy. The Summit also highlighted how important a safe, effective and equitably accessible vaccine will be in controlling COVID-19.

The Global Vaccine Summit marks 20 years since Gavi was founded. Dr Tedros added: "We join Gavi in celebrating the collective success of this great Alliance. These pledges are not just an investment in the Alliance of which we are a very proud partner; they are an advance on our shared vision of a healthier, safer and fairer world."



EMERGENCIES

Coronavirus [COVID-19]

Public Health Emergency of International Concern (PHEIC)

Coronavirus disease (COVID-19) outbreak situation

Last update: 5 June 2020, 20:00 GMT-4

Confirmed cases :: 6 663 304

Confirmed deaths :: 392 802

Countries, areas or territories with cases :: 216

:: WHO COVID-19 Webpage: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019>

:: Daily WHO situation reports here: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports>

:: **WHO Coronavirus disease (COVID-2019) daily press briefings** here:
<https://www.who.int/emergencies/diseases/novel-coronavirus-2019/media-resources/press-briefings>

:::::

:::::

Emergencies

Ebola – DRC+

Public Health Emergency of International Concern (PHEIC)

Government of Democratic Republic of Congo declares 11th Ebola virus disease outbreak

ADDIS ABABA, ETHIOPIA, 2 JUNE 2020. The Government of the Democratic Republic of Congo (DRC) declared a new outbreak of Ebola Virus Disease (EVD) on 31 May 2020 in Mbandaka, the country's northwest Équateur Province. The declaration followed notification by the Équateur provincial health authorities of community deaths on 23 and 30 May 2020.

This is the 11th EVD outbreak in the DRC and it has already claimed four lives and infected four other people in the community. The outbreak began at a time when experts were close to declaring an end to the 10th EVD outbreak in North Kivu Province, and when countries are fighting hard to control the COVID-19 pandemic.

The DRC Ministry of Health is currently establishing a coordination and response mechanism to effectively contain the outbreak...

UNICEF Press release

Ebola resurfaces in Équateur Province, north-western Democratic Republic of the Congo

15-year-old girl among five victims of new outbreak as country battles Ebola, COVID-19 and measles

01/06/2020

Ebola Outbreak in DRC 95: 02 June 2020

[Excerpts]

Situation Update

From 24 to 31 May 2020, no new confirmed cases of Ebola virus disease (EVD) have been reported in Ituri, North Kivu and South Kivu provinces of the Democratic Republic of the Congo. The source of infection of the cluster reported in April 2020 remains unconfirmed....

:::::

:::::

Emergencies

POLIO

Public Health Emergency of International Concern (PHEIC)

Polio this week as of 02 June 2020

:: After a vaccine-derived poliovirus outbreak was detected in the Philippines in 2019, health workers have been working to close a polio immunity gap present amongst some of the nation's children. In [this story](#), we follow Joana, a nurse working to end polio in Manila.

Summary of new viruses this week (AFP cases and ES positives):

:: Afghanistan: six cVDPV2 cases

:: Burkina Faso: two cVDPV2 cases

:: Ethiopia: one cVDPV2 case

:: Côte d'Ivoire: three cVDPV2 cases

:::::

:::::

[WHO Grade 3 Emergencies](#) [to 6 June 2020]

[Democratic Republic of the Congo](#)

:: [Ebola Outbreak in DRC 95: 02 June 2020](#)

[See Ebola above for detail]

Nigeria - No new digest announcements identified

Somalia - No new digest announcements identified

South Sudan - No new digest announcements identified

Syrian Arab Republic - No new digest announcements identified

Yemen - No new digest announcements identified

:::::

[WHO Grade 2 Emergencies](#) [to 6 June 2020]

[Angola](#)

:: [Community health mobilizers on the frontlines of Angola's COVID-19 response](#)

04 June 2020

Afghanistan - No new digest announcements identified

Burkina Faso [in French] - No new digest announcements identified

Burundi - No new digest announcements identified

Cameroon - No new digest announcements identified

Central African Republic - No new digest announcements identified

Ethiopia - No new digest announcements identified

Iran - No new digest announcements identified

Iraq - No new digest announcements identified

Libya - No new digest announcements identified

Malawi - No new digest announcements identified

Measles in Europe - No new digest announcements identified

MERS-CoV - No new digest announcements identified

Myanmar - No new digest announcements identified

Niger - No new digest announcements identified

occupied Palestinian territory - No new digest announcements identified

Sudan - No new digest announcements identified

Ukraine - No new digest announcements identified

Zimbabwe - No new digest announcements identified

:::::

WHO Grade 1 Emergencies [to 6 June 2020]

Chad - No new digest announcements identified

Djibouti - No new digest announcements identified

Kenya - No new digest announcements identified

Mali - No new digest announcements identified

Namibia - viral hepatitis - No new digest announcements identified

Tanzania - No new digest announcements identified

:::::

:::::

UN OCHA – L3 Emergencies

The UN and its humanitarian partners are currently responding to three 'L3' emergencies. This is the global humanitarian system's classification for the response to the most severe, large-scale humanitarian crises.

Syrian Arab Republic

:: Syrian Arab Republic: COVID-19 Response Update No. 05 - 5 June 2020

Yemen

:: 02 June 2020 Yemen Humanitarian Update Issue 5 (May 2020)

:: 03 June 2020 Yemen Situation Report, 3 June 2020

:::::

UN OCHA – Corporate Emergencies

When the USG/ERC declares a Corporate Emergency Response, all OCHA offices, branches and sections provide their full support to response activities both at HQ and in the field.

CYCLONE IDAI and Kenneth - No new digest announcements identified

EBOLA OUTBREAK IN THE DRC - No new digest announcements identified

:::::

:::::

WHO & Regional Offices [to 6 June 2020]

4 June 2020 *News release*

WHO welcomes crucial new funding for vaccines

[See Milestones above for detail]

3 June 2020 *Departmental news*

World Food Safety Day 2020: UN experts in Facebook live event on 5 June 2020

2 June 2020 *Statement*

Statement from Dr Mike Ryan, Executive Director, WHO Health Emergencies Programme at the Yemen High-level Pledging Conference

1 June 2020 *Departmental news*

Basic Psychosocial Skills: A Guide for COVID-19 Responders

:::::

Weekly Epidemiological Record, 5 June 2020, vol. 95, 23/24 (pp. 257–264)

Fast-tracking WHO's COVID-19 technical guidance to training for the frontline

:::::

WHO Regional Offices

Selected Press Releases, Announcements

WHO African Region AFRO

:: Polio eradication expertise backs Africa's COVID-19 response 04 June 2020

Expertise in polio eradication that has put Africa on the verge of being certified free of wild poliovirus has been brought to the frontlines of COVID-19 fight. A network of responders from the World Health Organization (WHO) Polio Eradication Programme and partner organizations is providing critical resources and skills to tackle the COVID-19 pandemic.

:: New Ebola outbreak detected in northwest Democratic Republic of the Congo; WHO surge...

01 June 2020

WHO Region of the Americas PAHO

No new digest content identified.

WHO South-East Asia Region SEARO

:: India elected chair of WHO's Executive Board 22 May 2020

WHO European Region EURO

:: WHO joins forces with 17 central European countries to step up tailored COVID-19 response 05-06-2020

:: World Food Safety Day: Unsafe food continues to affect millions in Europe during COVID-19 pandemic 05-06-2020

:: Protecting nature protects health – lessons for the future from COVID-19 05-06-2020

:: Transitioning towards 'a new normal' must be guided by public health principles, together with economic and societal considerations 03-06-2020

WHO Eastern Mediterranean Region EMRO

:: COVID-19: Keeping Morocco's mothers and babies safe 1 June 2020

WHO Western Pacific Region

No new digest content identified.

:::::

:::::

CDC/ACIP [to 6 June 2020]

<http://www.cdc.gov/media/index.html>

<https://www.cdc.gov/vaccines/acip/index.html>

Latest News Releases

[HHS Announces New Laboratory Data Reporting Guidance for COVID-19 Testing](#)

Thursday, June 4, 2020

Today, the U.S. Department of Health and Human Services (HHS) announced new Guidance that specifies what additional data must be reported to HHS by laboratories along with Coronavirus Disease 2019 (COVID-19) test results. The Guidance standardizes reporting to ensure that public health officials have access to comprehensive and nearly real-time data to inform decision making in their response to COVID-19. As the country begins to reopen, access to clear and accurate data is essential to communities and leadership for making decisions critical to a phased reopening.

"HHS and the entire Trump Administration are deeply concerned that COVID-19 is having a disproportionate impact on certain demographics, including racial minorities and older Americans," said HHS Secretary Alex Azar. "High quality data is at the core of any effective public health response, and standardized, comprehensive reporting of testing information will give our public health experts better data to guide decisions at all levels throughout the crisis." The new reporting requirements will provide information needed to better monitor disease incidence and trends by initiating epidemiologic case investigations, assisting with contact tracing, assessing availability and use of testing resources, and anticipating potential supply chain issues.

"The requirement to include demographic data like race, ethnicity, age, and sex will enable us to ensure that all groups have equitable access to testing, and allow us to accurately determine the burden of infection on vulnerable groups," said ADM Brett P. Giroir, MD, Assistant Secretary for Health. "With these data we will be able to improve decision-making and better prevent or mitigate further illnesses among Americans."...

[MMWR News Synopsis Friday, Jun 5, 2020](#)

[Missed Opportunities for Prevention of Congenital Syphilis — United States, 2018](#)

[Multistate Mumps Outbreak Originating from Asymptomatic Transmission at a Nebraska Wedding — Six States, August–October 2019](#)

[Evidence for Early Spread of COVID-19 Within the United States, January–February 2020 \(Early release May 29, 2020\)](#)

[COVID-19 Monitoring and Response Among U.S. Air Force Basic Military Trainees — Texas, March–April \(Early release June 2, 2020\)](#)

:::::

Africa CDC [to 6 June 2020]

<http://www.africacdc.org/>

News

Press Releases

[African Union rolls out Partnership to Accelerate COVID-19 Testing](#)

4 June 2020

Press Releases

Africa CDC and Mastercard Foundation partner to deliver one million test kits, deploy 10,000 community health workers for COVID-19 response

4 June 2020

Press Releases

Government of Democratic Republic of Congo declares 11th Ebola virus disease outbreak

2 June 2020

:::::

China CDC

<http://www.chinacdc.cn/en/>

No new digest content identified.

National Health Commission of the People's Republic of China

<http://en.nhc.gov.cn/>

News

June 6: Daily briefing on novel coronavirus cases in China

2020-06-05

On June 5, 31 provincial-level regions on the Chinese mainland as well as the Xinjiang Production and Construction Corps reported 3 new cases of confirmed infections (all are imported cases in Guangdong province), 1 new case of suspected infections (an imported case in Shanghai municipality), and no deaths...

Xi pledges continuous support for Costa Rica's COVID-19 fight

2020-06-06

Premier calls for strengthened vaccine research

2020-06-05

Testing of nearly 9.9 million people completed in Wuhan only 0.303% were found asymptomatic

2020-06-04

:::::

:::::

Announcements

Paul G. Allen Frontiers Group [to 6 June 2020]

<https://alleninstitute.org/what-we-do/frontiers-group/news-press/>

News

No new digest content identified.

BARDA [to 6 June 2020]
<https://www.phe.gov/about/barda/Pages/default.aspx>
No new digest content identified.

BMGF - Gates Foundation [to 6 June 2020]
<http://www.gatesfoundation.org/Media-Center/Press-Releases>
JUNE 04, 2020
[Bill & Melinda Gates Foundation pledges \\$1.6 billion to Gavi, the Vaccine Alliance, to protect the next generation with lifesaving vaccines](#)
Global leaders unite to safeguard 300 million more children from disease and mitigate consequences of COVID-19

Bill & Melinda Gates Medical Research Institute [to 6 June 2020]
<https://www.gatesmri.org/>
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people
No new digest content identified.

CARB-X [to 6 June 2020]
<https://carb-x.org/>
CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
No new digest content identified.

CEPI – Coalition for Epidemic Preparedness Innovations [to 6 June 2020]
<http://cepi.net/>
Latest News
[The University of Queensland, CEPI and CSL partner to advance development and manufacture of COVID-19 vaccine candidate](#)
CEPI and CSL will fund the development and manufacture of UQ's "molecular clamp" enabled vaccine against COVID-19.
COVID-19
05 Jun 2020

[CEPI partners with AstraZeneca to manufacture 300 million globally accessible doses of COVID-19 vaccine](#)
CEPI will invest a total of up to \$383m in this partnership to support the manufacture the AZD1222 vaccine candidate.
COVID-19
04 Jun 2020

CEPI awards up to US \$14.1 million to consortium of IVI and Bharat Biotech to advance development of Chikungunya vaccine in collaboration with Ind-CEPI

CEPI to partner with Bharat Biotech and IVI to advance clinical development and manufacturing of vaccine candidate against Chikungunya.

News

03 Jun 2020

Clinton Health Access Initiative, Inc. (CHAI) [to 6 June 2020]

<https://clintonhealthaccess.org/>

News & Press Releases

No new digest content identified.

EDCTP [to 6 June 2020]

<http://www.edctp.org/>

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials

Latest news

No new digest content identified.

Emory Vaccine Center [to 6 June 2020]

<http://www.vaccines.emory.edu/>

No new digest content identified.

European Medicines Agency [to 6 June 2020]

<http://www.ema.europa.eu/ema/>

News & Press Releases •

News: Patients' and healthcare professionals' organisations updated on EMA's response to COVID-19

Last updated: 04/06/2020

European Vaccine Initiative [to 6 June 2020]

<http://www.euvaccine.eu/news-events>

Latest News

No new digest content identified.

FDA [to 6 June 2020]

<https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/default.htm>

Press Announcements

June 5, 2020 - Coronavirus (COVID-19) Update: Daily Roundup June 5, 2020

[**June 4, 2020 - Coronavirus \(COVID-19\) Update: Daily Roundup June 4, 2020**](#)

[**June 4, 2020 - Coronavirus \(COVID-19\) Update: FDA Publicly Shares Antibody Test Performance Data From Kits as Part of Validation Study**](#)

[**June 4, 2020 - FDA Approves Antibiotic to Treat Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia**](#)

[**June 3, 2020 - Coronavirus \(COVID-19\) Update: Daily Roundup June 3, 2020**](#)

[**June 2, 2020 - Coronavirus \(COVID-19\) Update: Daily Roundup June 2, 2020**](#)

[**June 1, 2020 - Coronavirus \(COVID-19\) Update: FDA Takes Action to Protect Public Health; Increase Supply of Alcohol-Based Hand Sanitizer**](#)

[**June 1, 2020 - Coronavirus \(COVID-19\) Update: Daily Roundup June 1, 2020**](#)

Fondation Mérieux [to 6 June 2020]

<http://www.fondation-merieux.org/>

News, Events

No new digest content identified.

Gavi [to 6 June 2020]

<https://www.gavi.org/>

News releases

4 June 2020

[**World leaders make historic commitments to provide equal access to vaccines for all**](#)
[See Milestones above for detail]

4 June 2020

[**Gavi launches innovative financing mechanism for access to COVID-19 vaccines**](#)
[See Milestones above for detail]

3 June 2020

[**HPV vaccine manufacturers commit to provide enough supply to immunise at least 84 million girls in Gavi countries**](#)

[See Milestones above for detail]

3 June 2020

[**Private sector partners strengthen Gavi programmes with more than US\\$ 70 million in contributions**](#)

1 June 2020

[**Switzerland commits CHF 30 million to Gavi**](#)

1 June 2020

Italy deepens support for Gavi with €150 million IFFIm pledge

1 June 2020

Gavi receives US\$ 5 million from The Rockefeller Foundation

1 June 2020

The UPS Foundation commits US\$ 3 million to Gavi

1 June 2020

New donor Greece pledges €1.5 million to Gavi COVID response

GHIT Fund [to 6 June 2020]

<https://www.ghitfund.org/newsroom/press>

GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that No new digest content identified.

Global Fund [to 6 June 2020]

<https://www.theglobalfund.org/en/news/>

Voices

On the Front Lines: Responding to COVID-19

04 June 2020

With personal protective equipment, radio broadcasts and innovative mosquito net campaigns, countries are fighting COVID-19, shoring up health systems, and mitigating the impacts on lifesaving HIV, TB and malaria. The Global Fund is supporting these efforts with immediate funding. Here's where countries are directing that financial support to help stop the pandemic that threatens us all by uniting to fight...

Voices

Sex Workers in Africa Are More Vulnerable During COVID-19

04 June 2020

Hilleman Laboratories [to 6 June 2020]

<http://www.hillemanlabs.org/>

No new digest content identified.

Human Vaccines Project [to 6 June 2020]

<http://www.humanvaccinesproject.org/media/press-releases/>

No new digest content identified.

IAVI [to 6 June 2020]

<https://www.iavi.org/newsroom>

Press Releases

No new digest content identified.

International Coalition of Medicines Regulatory Authorities [ICMRA]

<http://www.icmra.info/drupal/en/news>

Selected Statements, Press Releases, Research

No new digest content identified.

International Generic and Biosimilar Medicines Association [IGBA]

<https://www.igbamedicines.org/>

News

No new digest content identified.

IFFIm

<http://www.iffim.org/>

Press Releases

[Italy deepens support for Gavi with €150 million IFFIm pledge](#)

01 Jun 2020

Pledge follows €120 million in direct funding to Gavi Italy announced at last month's Coronavirus Global Response pledging conference The funding builds on Italy's previous investments in Gavi's innovative financial tools – IFFIm and the Advance Market Commitment Gavi's record

IFRC [to 6 June 2020]

<http://media.ifrc.org/ifrc/news/press-releases/>

Selected Press Releases, Announcements

Global

[Joint statement: Uniting for a people's vaccine against COVID-19](#)

New York/Geneva, 3 June 2020 – The United Nations and the International Red Cross and Red Crescent Movement call for unity to scale up efforts to develop, test, and scale up production of safe, effective, quality, affordable diagnostics, therapeutics, ...

3 June 2020

Africa, Democratic Republic of the Congo

[DR Congo: Red Cross calls for "swift and extensive" response to the new Ebola outbreak](#)

Goma/Nairobi/Geneva, 3 June 2020 –More than 150 trained Red Cross volunteers have been deployed as part of a first wave of response to the latest Ebola outbreak in the Équateur Province, in the western part of Democratic Republic of the Congo. Dr Simon ...

3 June 2020

Africa, Global

[Facebook and Red Cross Launch #AfricaTogether, a Campaign Calling for Vigilance against Covid-19](#)

Nairobi/Geneva 01 June 2020 –Facebook and the International Red Cross and Red Crescent Movement are partnering to launch #AfricaTogether – a digital campaign and two-day festival on June 4th and 5th featuring artists from across Africa to encourage co ...

1 June 2020

IVAC [to 6 June 2020]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

Updates

[Webinar: How will a COVID-19 Vaccine be Delivered?](#)

June 2020

Register: The International Vaccine Access Center (IVAC) on June 17, 2020 at 1pm ET will host a 60-minute webinar, "How will a COVID-19 Vaccine be Delivered?". Description: When a COVID-19 vaccine becomes available, it will effectively stop disease transmission only if it reaches the people who need it. Many decisions go into developing a strategy [...]

IVI [to 6 June 2020]

<http://www.ivi.int/>

Selected IVI News & Announcements

[IVI partners with Seoul National University Hospital to start Phase 1/2 clinical trial of INOVIO's COVID-19 DNA \(INO-4800\) vaccine in South Korea](#)

:: First COVID-19 vaccine clinical study approved in South Korea funded by CEPI through INOVIO, and supported by KCDC/KNIH

:: 2-stage trial to test INOVIO's COVID-19 vaccine (INO-4800) using well-established DNA platform technology in adults

June 4, 2020, SEOUL, Korea and PLYMOUTH MEETING, PA, USA – The International Vaccine Institute (IVI) and Seoul National University Hospital announced a partnership to start a Phase 1/2 clinical trial of INO-4800 INOVIO's (NASDAQ:INO) COVID-19 vaccine in South Korea at a signing ceremony today. In attendance at the ceremony at SNU Hospital were IVI's Director General Dr. Jerome Kim and Deputy Director General of Science Dr. Manki Song, Dr. Anh Wartel (Associate Director General of EPIC and Head of Clinical Development and Regulatory) and Dr. Daniel Chul Woo Rhee (Project Lead), and SNU Hospital's President Yon Su Kim and Prof. Myoung-don Oh...

[CEPI awards up to US\\$14.1million to consortium of IVI and Bharat Biotech to advance development of Chikungunya vaccine in collaboration with Ind-CEPI](#)

June 3 2020, Oslo, Norway; Seoul, South Korea; Telangana, India—CEPI, the Coalition for Epidemic Preparedness Innovations, in collaboration with Ind-CEPI, has announced a new partnering agreement with a consortium comprising Bharat Biotech (BBIL) and the International Vaccine Institute (IVI) to advance the development of a Chikungunya vaccine. CEPI will provide the consortium with up to US\$14.1 million for vaccine manufacturing and clinical development of a two-dose live-inactivated vaccine (BBV87) against Chikungunya. This award is supported by the European Union's (EU's) Horizon 2020 programme through an existing framework partnership agreement with CEPI.

The consortium will be further supported with a grant of up to \$2.0m from the Indian Government's Ind-CEPI initiative which will fund the set-up of GMP manufacturing facilities for the vaccine in India, and the subsequent manufacture of clinical trial materials. In addition to

manufacturing, the partnering agreement will finance a multi-centre Phase 2/3 adaptive clinical trial to be conducted by IVI in Colombia, Panama and Thailand which will provide crucial data about the safety and immunogenicity of the vaccine candidate.

The partnership will build on BBIL's experience of developing and supplying affordable vaccines, and WHO prequalification procedures, to ensure affordable access to the vaccine in countries where Chikungunya is endemic, in line with CEPI's core commitment to equitable access..

JEE Alliance [to 6 June 2020]

<https://www.jeealliance.org/>

Selected News and Events

No new digest content identified.

MSF/Médecins Sans Frontières [to 6 June 2020]

<http://www.msf.org/>

Latest [Selected Announcements]

Coronavirus COVID-19 pandemic

COVID-19 cases in Haiti spike dramatically as MSF ...

Project Update 5 Jun 2020

Burkina Faso

Out of sight, people suffer from rise in violence in eastern B...

Op-Ed 5 Jun 2020

Mozambique

Thousands displaced, healthcare jeopardised, as violence surges in ...

Press Release 5 Jun 2020

Democratic Republic of Congo

Nearly 200,000 people forced from homes as violence surges in no...

Press Release 4 Jun 2020

DRC Ebola outbreaks

Crisis update - June 2020

Crisis Update 4 Jun 2020

Coronavirus COVID-19 pandemic

Facing multiple challenges in responding to COVID...

Project Update 3 Jun 2020

Coronavirus COVID-19 pandemic

Any future COVID-19 vaccines must be sold at cost and accessible to all ...

Press Release 3 Jun 2020

:: MSF has urged world leaders to demand pharmaceutical companies to sell any COVID-19 vaccines they develop at cost price.

:: The call comes as Gavi prepares to set up a fund specifically to pay for coronavirus vaccines for developing countries, into which governments are expected to pour in billions of dollars.
:: Governments must also overcome any nationalistic interests, and instead agree to distribute vaccines based on equitable need, including to frontline health workers as a priority.

Coronavirus COVID-19 pandemic

[MSF opens two COVID-19 treatment centres in northeastern Mexico...](#)

Project Update 3 Jun 2020

Afghanistan

[Fifteen mothers confirmed killed in Kabul maternity win...](#)

Project Update 3 Jun 2020

Coronavirus COVID-19 pandemic

["We have a lot of people that die quickly" of COVID-19 in Yemen](#)

Project Update 2 Jun 2020

Hepatitis C

[Increasing access to hepatitis C treatment in Ukraine](#)

Project Update 2 Jun 2020

National Vaccine Program Office - U.S. HHS [to 6 June 2020]

<https://www.hhs.gov/vaccines/about/index.html>

NVAC 2020 Meetings

[June 9-10, 2020 NVAC Meeting \(Virtual\)](#)

[September 23-24, 2020 Meeting \(Virtual\)](#)

NIH [to 6 June 2020]

<http://www.nih.gov/news-events/news-releases>

Selected News Releases

[Study identifies potential approach to treat severe respiratory distress in patients with COVID-19](#)

June 5, 2020 — These findings should not be considered clinical advice but are being shared to assist the public health response to COVID-19

[NIH to test one-dose antibiotic for the prevention of maternal and infant sepsis](#)

June 3, 2020 — Study of pregnant women in low- and middle-income countries co-funded by Bill & Melinda Gates Foundation.

PATH [to 6 June 2020]

<https://www.path.org/media-center/>

Selected Announcements

[PATH CEO urges US to re-commit to WHO](#)

May 30, 2020 by Nikolaj Gilbert

On behalf of my colleagues at PATH, I am disappointed by the news that the United States is withdrawing from the World Health Organization. It is precisely moments like these that demonstrate the need for the WHO's existence. While we must all evaluate our role in the COVID-19 response with a critical eye for opportunities to improve, now is not the time to create further disruption. Ending support and collaboration during a pandemic threatens our ability to defeat it, and is harmful for the health of Americans and populations around the globe...

Sabin Vaccine Institute [to 6 June 2020]

<http://www.sabin.org/updates/pressreleases>

Statements and Press Releases

Amid COVID-19 Vaccine Race, Sabin Vaccine Institute and the Aspen Institute Release Report on Vaccine Hesitancy: A Call to Improve Vaccine Acceptance

Tuesday, June 2, 2020

New report delves into the role of misinformation in shaping vaccination behavior and provides bold, actionable recommendations to counter growing trend of vaccine hesitancy

Washington, D.C. -- As the COVID-19 vaccine race accelerates, experts recognize that the challenge will not end with the development of a vaccine. The extraordinary effort to make a vaccine available across the globe will only be effective if the majority of people achieve immunity through vaccination. “Meeting the Challenge of Vaccination Hesitancy,” a new report released today by the Sabin-Aspen Vaccine Science and Policy Group, calls for an urgent, coordinated effort to strengthen vaccine acceptance and address the risk that vaccination hesitancy – the reluctance or opposition to vaccination despite the availability of safe and effective vaccines – poses to communities around the world...

UNAIDS [to 6 June 2020]

<http://www.unaids.org/en>

Selected Press Releases/Reports/Statements

5 June 2020

The value of integrating HIV prevention and contraceptive services

4 June 2020

Mitigating the impact of COVID-19 on key populations

3 June 2020

Lessons learned from HIV for COVID-19 in Senegal

2 June 2020

Mobilizing COVID-19 relief for transgender sex workers in Guyana and Suriname

1 June 2020

“We cannot provide only HIV services while sex workers are hungry”: Thai community organization steps in

UNICEF [to 6 June 2020]

<https://www.unicef.org/media/press-releases>

Selected Press releases/Announcements

Press release

COVID-19: One third of youth in Latin America and the Caribbean believe they are not at risk from disease, new UNICEF poll shows

05/06/2020

Press release

Unequal access to remote schooling amid COVID-19 threatens to deepen global learning crisis

04/06/2020

Press release

HPV vaccine manufacturers commit to provide enough supply to immunize at least 84 million girls in Gavi countries

On the eve of the Global Vaccine Summit 2020, five manufacturers commit to increasing and prioritising HPV vaccine supply to Gavi-supported countries, which have among the highest cervical cancer burdens in the world

04/06/2020

Statement

Message from UNICEF Executive Director Henrietta Fore to staff

03/06/2020

Statement

Remarks by UNICEF Executive Director Henrietta Fore at the High-Level Pledging Event for the Humanitarian Crisis in Yemen

02/06/2020

Press release

Ebola resurfaces in Équateur Province, north-western Democratic Republic of the Congo

15-year-old girl among five victims of new outbreak as country battles Ebola, COVID-19 and measles

01/06/2020

Unitaid [to 6 June 2020]

<https://unitaid.org/>

Featured News

No new digest content identified.

Vaccination Acceptance Research Network (VARN) [to 6 June 2020]

<https://vaccineacceptance.org/news.html#header1-2r>

Announcements

No new digest content identified.

Vaccine Confidence Project [to 6 June 2020]

<http://www.vaccineconfidence.org/>

Latest News & Archive

When a Close Friend Has Doubts About Vaccinations

5 Jun 2020

Coronavirus vaccine: anti-vax movement threatens Asian recovery

3 Jun 2020

Vaccine Education Center – Children’s Hospital of Philadelphia [to 6 June 2020]

<http://www.chop.edu/centers-programs/vaccine-education-center>

No new digest content identified.

Wellcome Trust [to 6 June 2020]

<https://wellcome.ac.uk/news>

Explainer | 3 June 2020

The vaccine journey: from idea to immunisation

Researchers may well identify a safe, effective vaccine for COVID-19 before too long, but all that fantastic work could count for nothing unless we also invest in manufacturing and delivery – to make sure that there is enough of the vaccine available to everyone who needs it.

Opinion | 1 June 2020

While we wait for a COVID-19 vaccine, let's not forget the importance of the vaccines we already have

Charlie Weller, Head of Vaccines Programme, Wellcome

With measures to prevent the spread of COVID-19 disrupting childhood and mass immunisation around the globe, millions are now at risk of other deadly diseases. This is why we must act and invest urgently to maintain routine immunisation.

The Wistar Institute [to 6 June 2020]

<https://www.wistar.org/news/press-releases>

Press Releases

No new digest content identified.

WFPHA: World Federation of Public Health Associations [to 6 June 2020]

<https://www.wfpha.org/>

Latest News

No new digest content identified.

World Organisation for Animal Health (OIE) [to 6 June 2020]

<https://www.oie.int/en/for-the-media/press-releases/2020/>

Press Releases

No new digest content identified.

:::::

ARM [Alliance for Regenerative Medicine] [to 6 June 2020]

<https://alliancerm.org/press-releases/>

Press Releases

ARM Statement on Racial Inequality & Injustice

June 5, 2020

BIO [to 6 June 2020]

<https://www.bio.org/press-releases>

Press Releases

BIO's Dr. McMurry-Heath Says Racism a "Chronic Disease" Plaguing Society

June 4, 2020

Will lead discussion on race and equity with industry leaders Drs. Tony Coles, Ted Love, and Jeremy Levin next week In the wake of tragic deaths and civil unrest, BIO's President and CEO Dr. Michelle McMurry-Heath announced she will lead a panel...

DCVMN – Developing Country Vaccine Manufacturers Network [to 6 June 2020]

<http://www.dcvmn.org/>

News

DCVMN participated in GAVI Vaccine Summit together with world leaders to support the new COVAX-AMC

04th June 2020

IFPMA [to 6 June 2020]

<http://www.ifpma.org/resources/news-releases/>

Selected Press Releases, Statements, Publications

Pharma pledges to continue 20 year partnership with Gavi, the Vaccine Alliance

04 June 2020

:: IFPMA members have worked for 20 years with Gavi to stem the ravages of childhood infectious diseases, helping vaccinate an entire generation of children so that they can thrive into adulthood and working to discover and increase access to new life-saving vaccines

:: At the Global Vaccine Summit, IFPMA and its members pledge to play their part in protecting the health of the next generation, with the broadest vaccine portfolio in history.

:: Solidarity and shared responsibility are embedded in working at unparalleled speed to develop and build manufacturing capacity and distribution networks to deploy a COVID-19 vaccine.

Biopharmaceutical Industry Statement at Gavi, the Vaccine Alliance – Global Vaccine Summit 2020

Geneva, 4 June 2020

Statement delivered by: Thomas Cueni, Director General of IFPMA, the International Federation of Pharmaceutical Manufacturers and Associations.

Today, we face the first global pandemic in living memory. Never before has there been so much hope placed in finding safe and effective vaccines, with the promise that no one is left behind.

IFPMA's members have worked for 20 years with Gavi to stem the ravages of infectious diseases. Now they are working at unparalleled speed to develop and build manufacturing capacity and distribution networks to deploy a COVID-19 vaccine in record time. The pace and progress of this work is unprecedented.

We are proud to be a founding partners of the Gavi Alliance and the Vaccines Accelerator and are fully committed to its goal to accelerate development, production, and equitable access to safe, effective, and affordable COVID-19 vaccines.

Be assured, we will deliver on the shared vision to leave no one behind and win the battle against COVID-19 together.

ICBA – International Council of Biotechnology Associations [to 6 June 2020]

<https://internationalbiotech.org/>

News

No new digest content identified.

PhRMA [to 6 June 2020]

<http://www.phrma.org/>

Selected Press Releases, Statements

The latest: What they are saying: Intellectual property protections critical as we work to defeat COVID-19

Tom Wilbur | June 5, 2020

Industry Watch [to 6 June 2020]

:: Covid-19 Diagnostics Market to Reach \$445.4 Mn, Globally, by the Fourth Quarter of 2020: Allied Market Research Jun 01, 2020

* * * *

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

American Journal of Infection Control

June 2020 Volume 48, Issue 6, p591-732

<http://www.ajicjournal.org/current>*Major Articles***A qualitative study on the psychological experience of caregivers of COVID-19 patients**

Niuniu Sun, Luoqun Wei, Suling Shi, Dandan Jiao, Runluo Song, Lili Ma, Hongwei Wang, Chao Wang, Zhaoguo Wang, Yanli You, Shuhua Liu, Hongyun Wang

p592–598

Published online: April 7, 2020

Examining the inclusion of patients and their family members in infection prevention and control policies and guidelines across Bangladesh, Indonesia, and South Korea

Ji Yeon Park, Jerico Franciscus Pardosi, Holly Seale

p599–608

Published online: January 13, 2020

American Journal of Preventive Medicine

June 2020 Volume 58, Issue 6, p757-898

<http://www.ajpmonline.org/current>*Current Issues***COVID-19 and the Correctional Environment: The American Prison as a Focal Point for Public Health**

Andre G. Montoya-Barthelemy, Charles D. Lee, Dave R. Cundiff, Eric B. Smith

p888–891

Published online: April 17, 2020

Vulnerable Populations: Weathering the Pandemic Storm

Elizabeth M. Salisbury-Afshar, Josiah D. Rich, Eli Y. Adashi

p892–894

Published online: April 21, 2020

American Journal of Public Health

June 2020 110(6)

<http://ajph.aphapublications.org/toc/ajph/current>*COCHRANE***New Standards for Systematic Reviews Incorporate Population Health Sciences**

Statistics/Evaluation/Research, Other Statistics/Evaluation/Research

Mona Nasser

110(6), pp. 753–754

*MIGRANTS HEALTH***Latest Public Health Threats to Migrants at the US Southern Border**

Global Health, Government, Refugees, Immigration, Injury/Emergency Care/Violence

Joseph Nwadiuko and Sural Shah

American Journal of Tropical Medicine and Hygiene

Volume 102, Issue 5, May 2020

<http://www.ajtmh.org/content/journals/14761645/102/5>

[Reviewed earlier]

Annals of Internal Medicine

2 June 2020 Volume 172, Issue 11

<http://annals.org/aim/issue>*Reviews***Diagnostic Testing for Severe Acute Respiratory Syndrome–Related Coronavirus 2 A Narrative Review**

FREE

Matthew P. Cheng, MDCM, Jesse Papenburg, MD, MSc, Michaël Desjardins, MD, [... et al.](#)

Diagnostic testing to identify infected persons is central to efforts to control the COVID-19 pandemic. This review synthesizes current knowledge of diagnostic options available to clinicians, highlights key gaps in current diagnostic capacity, and discusses potential solutions.

*Ideas and Opinions***Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know**

FREE

Jinoos Yazdany, MD, MPH and Alfred H.J. Kim, MD, PhD

Two medications often used for treatment of immune-mediated conditions, hydroxychloroquine and chloroquine, have recently attracted widespread interest as potential therapies for COVID-19. The authors of this commentary provide guidance for clinical decision making for patients with COVID-19 as well as for patients with rheumatologic conditions, such as systemic lupus erythematosus and rheumatoid arthritis.

Artificial Intelligence – An International Journal

Volume 283 June 2020

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/283/suppl/C>

[Reviewed earlier]

BMC Cost Effectiveness and Resource Allocation<http://resource-allocation.biomedcentral.com/>

(Accessed 6 June 2020)

[No new digest content identified]

BMJ Global Health

June 2020 - Volume 5 - 6

<https://gh.bmjjournals.org/content/5/6>

Commentary

Protecting hard-won gains for mothers and newborns in low-income and middle-income countries in the face of COVID-19: call for a service safety net

(3 June, 2020)

Wendy Jane Graham, Bosede Afolabi, Lenka Benova, Oona Maeve Renee Campbell, Veronique Filippi, Annette Nakimuli, Loveday Penn-Kekana, Gaurav Sharma, Uduak Okomo, Sandra Valongueiro, Peter Waiswa, Carine Ronsmans

Towards a socially just model: balancing hunger and response to the COVID-19 pandemic in Bangladesh

(1 June, 2020)

Sabina Faiz Rashid, Sally Theobald, Kim Ozano

Practice

Prioritising the role of community health workers in the COVID-19 response (4 June, 2020)

Madeleine Ballard, Emily Bancroft, Josh Nesbit, Ari Johnson, Isaac Holeman, Jennifer Foth, Debbie Rogers, Jane Yang, James Nardella, Helen Olsen, Mallika Raghavan, Raj Panjabi, Rebecca Alban, Serah Malaba, Molly Christiansen, Stephanie Rapp, Jennifer Schechter, Patrick Aylward, Ash Rogers, Jacques Sebisaho, Clarise Ako, Nandini Choudhury, Carey Westgate, Julius Mbeya, Ryan Schwarz, Matthew H Bonds, Rehan Adamjee, Julia Bishop, Amanda Yembrick, David Flood, Meg McLaughlin, Daniel Palazuelos

BMC Health Services Research

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 6 June 2020)

[No new digest content identified]

BMC Infectious Diseases

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 6 June 2020)

[No new digest content identified]

BMC Medical Ethics

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 6 June 2020)

[No new digest content identified]

BMC Medicine

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 6 June 2020)

An evidence mapping and analysis of registered COVID-19 clinical trials in China

This article aims to summarize the key characteristics of registered trials of 2019 novel coronavirus (COVID-19), in terms of their spatial and temporal distributions, types of design and interventions, and pa...

Authors: Liming Lu, Fan Li, Hao Wen, Shuqi Ge, Jingchun Zeng, Wen Luo, Lai Wang, Chunzhi Tang and Nenggui Xu
Citation: BMC Medicine 2020 18:167
Content type: Research article
Published on: 1 June 2020

BMC Pregnancy and Childbirth

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>
(Accessed 6 June 2020)
[No new digest content identified]

BMC Public Health

<http://bmcpublichealth.biomedcentral.com/articles>
(Accessed 6 June 2020)

Global health systems partnerships: a mixed methods analysis of Mozambique's HPV vaccine delivery network actors

Global health partnerships have expanded exponentially in the last two decades with Gavi, the Vaccine Alliance considered the model's pioneer and leader because of its vaccination programs' implementation mech...

Authors: Caroline Soi, Jessica Shearer, Baltazar Chilundo, Vasco Muchanga, Luisa Matsinhe, Sarah Gimbel and Kenneth Sherr
Citation: BMC Public Health 2020 20:862
Content type: Research article
Published on: 5 June 2020

Prevalence and predictors of taking tetanus toxoid vaccine in pregnancy: a cross-sectional study of 8,722 women in Sierra Leone

Immunization of women during pregnancy to protect them and their infants against tetanus, pertussis and influenza is recommended by the World health Organization (WHO). However, there is limited information ab...

Authors: Sanni Yaya, Komlan Kota, Amos Buh and Ghose Bishwajit
Citation: BMC Public Health 2020 20:855
Content type: Research article
Published on: 5 June 2020

Preferential differences in vaccination decision-making for oneself or one's child in The Netherlands: a discrete choice experiment

To optimize the focus of future public information campaigns in The Netherlands promoting the uptake of vaccines among adults and children, we quantified the contribution of several attributes to the vaccinati...

Authors: Joram Hoogink, Frederik Verelst, Roselinde Kessels, Albert Jan van Hoek, Aura Timen, Lander Willem, Philippe Beutels, Jacco Wallinga and G. Ardine de Wit
Citation: BMC Public Health 2020 20:828
Content type: Research article
Published on: 1 June 2020

Feasibility of a twitter campaign to promote HPV vaccine uptake among racially/ethnically diverse young adult women living in public housing

Uptake and completion of the HPV vaccine is suboptimal. This study assessed the feasibility of implementing a one-month Twitter campaign to promote knowledge about the human papillomavirus (HPV) vaccine among ...

Authors: Jennifer D. Allen, Justin Hollander, Lisa Gualtieri, Tania M. Alarcon Falconi, Stephanie Savir and Madina Agénor

Citation: BMC Public Health 2020 20:830

Content type: Research article

Published on: 1 June 2020

BMC Research Notes

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 6 June 2020)

[No new digest content identified]

BMJ Open

May 2020 - Volume 10 - 5

<https://bmjopen.bmjjournals.org/content/10/6>

[Reviewed earlier]

Bulletin of the World Health Organization

Volume 98, Number 6, June 2020, 373-440

<https://www.who.int/bulletin/volumes/98/6/en/>

EDITORIALS

Mortality surveillance during the COVID-19 pandemic

— Philip Setel, Carla AbouZahr, Emily B Atuhere, Martin Bratschi, Emily Cercone, Oliver Chinganya, Benjamin Clapham, Samuel J Clark, Carlie Congdon, Don de Savigny, Adam Karpati, Erin Nichols, Robert Jakob, James Mwanza, William Muhwava, Petra Nahmias, Elizabeth M Ortiz & Akhona Tshangela

<http://dx.doi.org/10.2471/BLT.20.263194>

RESEARCH

A survey of nongovernmental organizations on their use of WHO's prequalification programme

— Ariadna Nebot Giralt, Maya Ronse & Raffaella Ravinetto

<http://dx.doi.org/10.2471/BLT.19.233882>

Child Care, Health and Development

Volume 46, Issue 3 Pages: 249-396 May 2020

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

Clinical Pharmacology & Therapeutics

Volume 107, Issue 6 Pages: 1263-1457 June 2020

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/2020/107/6>

[Reviewed earlier]

Clinical Therapeutics

April 2020 Volume 42, Issue 4, p551-728, e65-e86

<http://www.clinicaltherapeutics.com/current>

[Reviewed earlier]

Clinical Trials

Volume 17 Issue 3, June 2020

<https://journals.sagepub.com/toc/ctja/17/3>

[Reviewed earlier]

Conflict and Health

<http://www.conflictandhealth.com/>

[Accessed 6 June 2020]

[No new digest content identified]

Contemporary Clinical Trials

Volume 92 May 2020

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/92/suppl/C>

Research article Abstract only

[Use of real-world data for HPV vaccine trial follow-up in the Nordic region](#)

Espen Enerly, Sophie Berger, Susanne K. Kjær, Karin Sundström, ... Mari Nygård

Article 105996

The CRISPR Journal

Volume 3, Issue 2 / April 2020

<https://www.liebertpub.com/toc/crispr/3/2>

[Reviewed earlier]

Current Genetic Medicine Reports

Volume 8, Issue 2, June 2020

<https://link.springer.com/journal/40142/8/2>

[Reviewed earlier]

Current Opinion in Infectious Diseases

June 2020 - Volume 33 - Issue 3

<https://journals.lww.com/co-infectiousdiseases/pages/currrenttoc.aspx>

[Reviewed earlier]

Developing World Bioethics

Volume 20, Issue 1 Pages: 1-60 March 2020

<https://onlinelibrary.wiley.com/toc/14718847/current>

[Reviewed earlier]

Development in Practice

Volume 30, Issue 2, 2020

<http://www.tandfonline.com/toc/cdip20/current>

[Reviewed earlier]

Disaster Medicine and Public Health Preparedness

Volume 14 - Issue 2 - April 2020

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[New issue; No digest content identified]

Disasters

Volume 44, Issue 2 Pages: 233-432 April 2020

<https://onlinelibrary.wiley.com/toc/14677717/current>

[Reviewed earlier]

EMBO Reports

Volume 21 Issue 6 4 June 2020

<https://www.embopress.org/toc/14693178/current>

Science & Society 28 April 2020

Freedom of research in a democratic society : Is there a contradiction between socially desirable science and freedom of research?

Sebastian Wäscher, Anna Deplazes-Zemp

Freedom of research and democratization of science are often conflicting concepts in democratic societies. It is thus necessary to define when either applies.

Science & Society 19 May 2020 Open Access

The evolving landscape around genome editing in agriculture : Many countries have exempted or move to exempt forms of genome editing from GMO regulation of crop plants

Sarah M Schmidt, Melinda Belisle, Wolf B Frommer

The EU and New Zealand are the only legislations where genome-edited plants are considered and regulated as GMOs while many other countries move to exempt genome-edited crops.

Emerging Infectious Diseases

Volume 26, Number 6—June 2020

<http://wwwnc.cdc.gov/eid/>*Perspective***[Identifying and Interrupting Superspreading Events—Implications for Control of Severe Acute Respiratory Syndrome Coronavirus 2](#) [PDF - 334 KB - 8 pages]**

T. R. Frieden and C. T. Lee

Epidemics

Volume 31 June 2020

<https://www.sciencedirect.com/journal/epidemics/vol/31/suppl/C>

[Reviewed earlier]

Epidemiology and Infection

Volume 148 - 2020

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

Ethics & Human Research

Volume 42, Issue 3 Pages: 1-44 May–June 2020

<https://onlinelibrary.wiley.com/toc/25782363/current>***Perspectives of minors and parents • Non-English speakers • Covid-19 and other infectious diseases***

[Reviewed earlier]

The European Journal of Public Health

Volume 30, Issue 2, April 2020

<https://academic.oup.com/eurpub/issue/30/2>

[Reviewed earlier]

Gates Open Research<https://gatesopenresearch.org/browse/articles>

[Accessed 6 June 2020]

[No new digest content identified]

Genome Medicine<https://genomemedicine.biomedcentral.com/articles>

[Accessed 6 June 2020]

[No new digest content identified]

Global Health Action

Volume 12, 2019 Issue 1
<https://www.tandfonline.com/toc/zgha20/12/sup1?nav=tocList>
[Reviewed earlier]

Global Health: Science and Practice (GHSP)
Vol. 8, No. 1 March 30, 2020
<http://www.ghspjournal.org/content/current>
[Reviewed earlier]

Global Public Health
Volume 15, 2020 Issue 6
<http://www.tandfonline.com/toc/rgph20/current>
[Reviewed earlier]

Globalization and Health
<http://www.globalizationandhealth.com/>
[Accessed 6 June 2020]
[No new digest content identified]

Health Affairs
Vol. 39, No. 6 June 2020
<https://www.healthaffairs.org/toc/hlthaff/current>
Rural Health, Behavioral Health & More
Research Article COVID-19
[**The Potential Health Care Costs And Resource Use Associated With COVID-19 In The United States**](#)
Sarah M. Bartsch, Marie C. Ferguson, James A. McKinnell, Kelly J. O'Shea,

Health and Human Rights
<https://www.hhrjournal.org/>
[Accessed 6 June 2020]
Papers-in-Press
[No new digest content identified]

Health Economics, Policy and Law
Volume 15 - Issue 2 - April 2020
<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>
[Reviewed earlier]

Health Policy and Planning
Volume 35, Issue 5, June 2020

<https://academic.oup.com/heapol/issue/35/5>

[New issue; No digest content identified]

Health Research Policy and Systems

<http://www.health-policy-systems.com/content>

[Accessed 6 June 2020]

Amplifying the role of knowledge translation platforms in the COVID-19 pandemic response

The COVID-19 pandemic presents the worst public health crisis in recent history. The response to the COVID-19 pandemic has been challenged by many factors, including scientific uncertainties, scarcity of relev...

Authors: Fadi El-Jardali, Lama Bou-Karroum and Racha Fadlallah

Citation: Health Research Policy and Systems 2020 18:58

Content type: Commentary

Published on: 3 June 2020

Human Gene Therapy

Volume 31, Issue 9-10 / May 2020

<https://www.liebertpub.com/toc/hum/31/9-10>

[Reviewed earlier]

Humanitarian Exchange Magazine

Number 77, March 2020

<https://odihpn.org/magazine/responding-to-ebola-in-the-democratic-republic-of-congo/>

Responding to Ebola in the Democratic Republic of Congo

by Humanitarian Practice Network

This edition of Humanitarian Exchange, co-edited with Anne Harmer, focuses on the response to the Ebola outbreak in the Democratic Republic of Congo (DRC). Although at the time of publication the outbreak appeared to have ended, over its course it claimed 2,200 lives, with more than 3,300 infected, making this the world's second largest outbreak ever.

In the lead article, Natalie Roberts reflects on the extent to which humanitarian actors have applied learning from the outbreak in West Africa in 2014–2016. Richard Kojan and colleagues report on the NGO ALIMA's flexible, patient-centred approach to reducing mortality, Marcela Ascuntar reflects on lessons learned from community feedback and Bernard Balibuno, Emanuel Mbuna Bajonga and Howard Mollett highlight the crucial role faith-based organisations have played in the response. In their article, Theresa Jones, Noé Kasali and Olivia Tulloch outline the work of the Bethesda counselling centre in Beni, which provides support to grieving families. Reflecting on findings from a recent assessment by Translators without Borders, Ellie Kemp describes the challenges involved in providing clear and accessible information on Ebola and the response, and Sung Joon Park and colleagues explain how humane care and treatment can help increase trust and confidence in the response. Stephen Mugamba and his co-authors highlight the importance of community involvement in Ebola research, and Gillian McKay and her co-authors examine the impact of the Ebola outbreak and response on sexual and reproductive health services.

Stacey Mearns, Kiryn Lanning and Michelle Gayer present an Ebola Readiness Roadmap to support NGOs in preparing for an outbreak, while Edward Kumakech, Maurice Sadlier, Aidan Sinnott and Dan Irvine report on a Gap Analysis tool looking at the communication, community engagement and compliance tracking activities that need to be in place before an Ebola vaccine is deployed. Emanuele Bruni and colleagues describe the development of a new monitoring and evaluation framework for strategic response planning. The edition ends with an article by Adelicia Fairbanks, who argues for an acceptance strategy in the DRC to improve security and access for responding agencies.

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)

Volume 16, Issue 5, 2020

<http://www.tandfonline.com/toc/khvi20/current>

Special Issue: Vaccine Acceptance

Editorials

Building vaccine acceptance through communication and advocacy

Kristen A. Feemster

Pages 1004-1006 | Published online: 13 May 2020

...Conclusion

The key issues for increasing the number of vaccinated people worldwide, especially children, is to increase the supply of available vaccines, assure funding and affordability for lower-income countries, improve distribution and storage networks, assure the availability of healthcare workers to administer vaccines, improve the ability of the population to access vaccination centers, and minimize refusal / hesitation to maximize acceptability of vaccines.

It is noteworthy that among these key issues, all involve physical activities except for the final issue, which is the subject of this Special Issue. Vaccine acceptance / hesitation / refusal is unique in being a state of mind for the potential vaccinee or caregiver, such that different methods must be applied to improve acceptability. The ability of workers in the field to improve acceptability will be directly reflected in increased vaccinations with concomitant reductions in morbidity and mortality from vaccine-preventable diseases. This is a major public health challenge for the coming decade and beyond, which also will be very important for the success of new vaccines in the development pipeline.

This Special Issue includes an extensive number of articles around this theme which we recommend be reviewed.

Infectious Agents and Cancer

<http://www.infectagentscancer.com/content>

[Accessed 6 June 2020]

[No new digest content identified]

Infectious Diseases of Poverty

<http://www.idpjournal.com/content>

[Accessed 6 June 2020]

Factors associated with mobile phone ownership and potential use for rabies vaccination campaigns in southern Malawi

Rabies is a fatal but preventable viral disease, which causes an estimated 59 000 human deaths globally every year. The vast majority of human rabies cases are attributable to bites from infected domestic dogs...

Authors: Orla Marron, Gareth Thomas, Jordana L. Burdon Bailey, Dagmar Mayer, Paul O. Grossman, Frederic Lohr, Andy D. Gibson, Luke Gamble, Patrick Chikungwa, Julius Chulu, Ian G. Handel, Barend M. de C Bronsvoort, Richard J. Mellanby and Stella Mazeri

Citation: *Infectious Diseases of Poverty* 2020 9:62

Content type: Research Article

Published on: 5 June 2020

International Health

Volume 12, Issue 3, May 2020,

<https://academic.oup.com/inthealth/issue/12/3>

[Reviewed earlier]

International Journal of Community Medicine and Public Health

Vol 7, No 5 (2020) May 2020

<https://www.ijcmph.com/index.php/ijcmph/issue/view/62>

[Reviewed earlier]

International Journal of Epidemiology

Volume 49, Issue Supplement_1, April 2020

https://academic.oup.com/ije/issue/49/Supplement_1

Big Data, Small Area

[Reviewed earlier]

International Journal of Human Rights in Healthcare

Volume 13 Issue 2 2020

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/13/iss/2>

Special Issue: Sex trafficking and violence against women

[Reviewed earlier]

International Journal of Infectious Diseases

May 2020 Volume 94, p1-164

[https://www.ijidonline.com/issue/S1201-9712\(20\)X0006-3](https://www.ijidonline.com/issue/S1201-9712(20)X0006-3)

Coronavirus (COVID-19) Collection

Could enhanced influenza and pneumococcal vaccination programs help limit the potential damage from SARS-CoV-2 to fragile health systems of southern hemisphere countries this winter?

Marc Mendelson

p32–33

Published online: March 17, 2020

COVID-19 travel restrictions and the International Health Regulations – Call for an open debate on easing of travel restrictions

Eskild Petersen, Brian McCloskey, David S. Hui, Richard Kock, Francine Ntoumi, Ziad A. Memish, Nathan Kapata, Esam I. Azhar, Marjorie Pollack, Larry C. Madoff, Davidson H. Hamer, Jean B. Nchega, N. Pshenichnaya, Alimuddin Zumla

p88–90

Published online: April 16, 2020

JAMA

June 2, 2020, Vol 323, No. 21, Pages 2111-2210

<https://jamanetwork.com/journals/jama/currentissue>

Viewpoint

COVID-19: Beyond Tomorrow

Choices for the “New Normal”

Donald M. Berwick, MD, MPP

free access has active quiz has multimedia has audio

JAMA. 2020;323(21):2125-2126. doi:10.1001/jama.2020.6949

In this Viewpoint, Donald Berwick summarizes the rapid changes the COVID-19 pandemic has wrought on the pace, scientific standards, delivery mechanisms, and working conditions of health care and how it has sharply increased awareness of the societal costs of poor public health preparedness and health inequities.

Editorial

COVID-19—Looking Beyond Tomorrow for Health Care and Society

Phil B. Fontanarosa, MD, MBA; Howard Bauchner, MD

Information Technology-Based Tracing Strategy in Response to COVID-19 in South Korea—Privacy Controversies

Sangchul Park, JSD; Gina Jeehyun Choi, JSD; Haksoo Ko, JD, PhD

free access

JAMA. 2020;323(21):2129-2130. doi:10.1001/jama.2020.6602

This Viewpoint discusses legal and privacy concerns raised by South Korea’s information technology (IT)-based containment of the COVID-19 pandemic and proposes use of aggregated rather than person-level data to protect the privacy of individuals while maintaining the effectiveness of public health measures.

Preserving Clinical Trial Integrity During the Coronavirus Pandemic

Mary M. McDermott, MD; Anne B. Newman, MD, MPH

free access has active quiz

JAMA. 2020;323(21):2135-2136. doi:10.1001/jama.2020.4689

This Viewpoint discusses ways the coronavirus pandemic is threatening clinical trial conduct and enrollment, and suggests ways to adapt, including changes to how outcomes data are collected and how interventions are delivered and monitored, to minimize trial disruption, maximize trial benefit, and ensure patient health and safety during the pandemic.

Editorial

Randomized Clinical Trials and COVID-19 Managing Expectations

Howard Bauchner, MD; Phil B. Fontanarosa, MD, MBA

Action-Informed Artificial Intelligence—Matching the Algorithm to the Problem

Christopher J. Lindsell, PhD; William W. Stead, MD; Kevin B. Johnson, MD, MS

JAMA. 2020;323(21):2141-2142. doi:10.1001/jama.2020.5035

This Viewpoint discusses ways in which artificial intelligence (AI) methods can enhance the use of health care data in detection, prognostication, and prediction; suggests ways in which AI tools might be better developed and deployed; and calls for increased focus on anticipated changes that will be made in the health care system to better benefit from the use of AI.

Editorial

Randomized Clinical Trials of Artificial Intelligence

Derek C. Angus, MD, MPH

JAMA Pediatrics

June 2020, Vol 174, No. 6, Pages 517-628

<http://archpedi.jamanetwork.com/issue.aspx>

Viewpoint

Affording Genetic Therapies in the Medicaid Program

Jeromie Ballreich, PhD, MHS; Ijeamaka Ezebilo, MD, MPH; Joshua Sharfstein, MD

JAMA Pediatr. 2020;174(6):523-524. doi:10.1001/jamapediatrics.2020.0168

This Viewpoint describes the costs of genetic therapies for children covered by Medicaid and suggests strategies to decrease these costs and thus increase access to these drugs.

JBI Database of Systematic Review and Implementation Reports

May 2020 - Volume 18 - Issue 5

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Adolescent Health

June 2020 Volume 66, Issue 6, p635-766

[https://www.jahonline.org/issue/S1054-139X\(20\)X0004-8](https://www.jahonline.org/issue/S1054-139X(20)X0004-8)

[New issue; No digest content identified]

Journal of Artificial Intelligence Research

Vol. 68 (2020)

<https://www.jair.org/index.php/jair>

[Reviewed earlier]

Journal of Community Health

Volume 45, Issue 3, June 2020

<https://link.springer.com/journal/10900/45/3>

[Reviewed earlier]

Journal of Development Economics

Volume 145 June 2020

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/145/suppl/C>

[New issue; No digest content identified]

Journal of Empirical Research on Human Research Ethics

Volume 15 Issue 3, July 2020

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

Journal of Epidemiology & Community Health

May 2020 - Volume 74 - 5

<https://jech.bmjjournals.org/content/74/5>

[Reviewed earlier]

Journal of Evidence-Based Medicine

Volume 13, Issue 2 Pages: 89-177 May 2020

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

Journal of Global Ethics

Volume 16, Issue 1, 2020

<http://www.tandfonline.com/toc/rjge20/current>

[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 31, Number 2, May 2020

<https://muse.jhu.edu/issue/42391>

[New issue; No digest content identified]

Journal of Immigrant and Minority Health

Volume 22, Issue 3, June 2020

<https://link.springer.com/journal/10903/22/3>

[Reviewed earlier]

Journal of Immigrant & Refugee Studies

Volume 18, 2020_ Issue 2

<https://www.tandfonline.com/toc/wimm20/current>
[Reviewed earlier]

Journal of Infectious Diseases
Volume 221, Issue 9, 1 May 2020
<https://academic.oup.com/jid/issue/221/9>
[Reviewed earlier]

Journal of Medical Ethics
June 2020 - Volume 46 - 6
<http://jme.bmjjournals.org/content/current>
Guest editorial
Pandemic medical ethics (29 May, 2020) Free
Jennifer Blumenthal-Barby, Kenneth Boyd, Brian D Earp, Lucy Frith, Rosalind J McDougall, John McMillan, Jesse Wall

Current controversy
Whose life to save? Scarce resources allocation in the COVID-19 outbreak (9 April, 2020) Free
Chiara Mannelli

Journal of Patient-Centered Research and Reviews
Volume 7, Issue 2 (2020)
<https://digitalrepository.aurorahealthcare.org/jpcrr/>
[Reviewed earlier]

Journal of Pediatrics
June 2020 Volume 221, p1-268
<http://www.jpeds.com/current>
Original Articles
Effect of State Immunization Information System Based Reminder/Recall for Influenza Vaccinations: A Randomized Trial of Autodialer, Text, and Mailed Messages
Peter G. Szilagyi, Christina S. Albertin, Alison W. Saville, Rebecca Valderrama, Abigail Breck, Laura Helmkamp, Xinkai Zhou, Sitaram Vangala, L. Miriam Dickinson, Chi-Hong Tseng, Jonathan D. Campbell, Melanie D. Whittington, Heather Roth, Cynthia M. Rand, Sharon G. Humiston, Dina Hoefer, Allison Kempe
p123–131.e4
Published in issue: June 2020

Journal of Pharmaceutical Policy and Practice
<https://joppp.biomedcentral.com/>
[Accessed 6 June 2020]

Pharmacists reinventing their roles to effectively respond to COVID-19: a global report from the international pharmacists for anticoagulation care taskforce (iPACT)

Authors: Filipa Alves da Costa, Vivian Lee, Silvana Nair Leite, Maria Dolores Murillo, Tom Menge and Sotiris Antoniou

Content type: Commentary

17 June 2020

Journal of Public Health Management & Practice

May/June 2020 - Volume 26 - Issue 3

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Public Health Policy

Volume 41, Issue 2, June 2020

<https://link.springer.com/journal/41271/41/2>

[Reviewed earlier]

Journal of Refugee & Global Health

Volume 2, Issue 2 (2019)

<https://ir.library.louisville.edu/rgh/>

[Reviewed earlier]

Journal of the Royal Society – Interface

June 2020 Volume 17 Issue 167

<https://royalsocietypublishing.org/toc/rsif/current>

[New issue; No digest content identified]

Journal of Travel Medicine

Volume 27, Issue 3, April 2020

<https://academic.oup.com/jtm/issue/27/3>

[Reviewed earlier]

Journal of Virology

June 2020; Volume 94, Issue 12

<http://jvi.asm.org/content/current>

[New issue; No digest content identified]

The Lancet

Jun 06, 2020 Volume 395 Number 10239 p1739-1812, e101

<https://www.thelancet.com/journals/lancet/issue/current>

Editorial

Salient lessons from Russia's COVID-19 outbreak

The Lancet

Comment

Regenerative medicine: challenges and opportunities

Giulio Cossu, Robin Fears, George Griffin, Volker ter Meulen

In 2018, the Lancet Commission on stem cells and regenerative medicine¹ reported how, despite an exponential growth in experimental therapies, there had been limited clinical uptake. Regenerative medicine comprises various novel approaches such as cell and gene therapy that have produced life-saving therapies for a few genetic diseases affecting blood or skin. Enthusiasm about the broad potential of regenerative medicine led to a gap between expectations and the realities of translating technologies into clinical practice. The Lancet Commission called for rethinking to tackle the combination of problems residing in poor-quality science, unclear funding models, unrealistic hopes, and unscrupulous private clinics.¹

Articles

Mapping geographical inequalities in childhood diarrhoeal morbidity and mortality in low-income and middle-income countries, 2000–17: analysis for the Global Burden of Disease Study 2017

Local Burden of Disease Diarrhoea Collaborators

The Lancet Child & Adolescent Health

Jun 2020 Volume 4 Number 6 p407-478, e12-e16

<https://www.thelancet.com/journals/lanchi/issue/current>

Comment

The immune system of children: the key to understanding SARS-CoV-2 susceptibility?

Rita Carsetti, Concetta Quintarelli, Isabella Quinti, Eva Piano Mortari, Alimuddin Zumla, Giuseppe Ippolito, Franco Locatelli

Articles

Acute lower respiratory infections in Indigenous infants in Australia's Northern Territory across three eras of pneumococcal conjugate vaccine use (2006–15): a population-based cohort study

Michael J Binks, Jemima Beissbarth, Victor M Oguoma, Susan J Pizzutto, Amanda J Leach, Heidi C Smith-Vaughan, Lisa McHugh, Ross M Andrews, Rosalind Webby, Peter S Morris, Anne B Chang

Lancet Digital Health

Jun 2020 Volume 2 Number 6e268-e330

<https://www.thelancet.com/journals/landig/issue/current>

Editorial

Pandemic versus pandemonium: fighting on two fronts

The Lancet Digital Health

Lancet Global Health

Jun 2020 Volume 8 Number 6 e737-e857

<http://www.thelancet.com/journals/langlo/issue/current>

[New issue; No digest content identified]

Lancet Infectious Diseases

Jun 2020 Volume 20 Number 6 p629-754, e116-e147

<http://www.thelancet.com/journals/laninf/issue/current>

Comment

[Scientific and ethical basis for social-distancing interventions against COVID-19](#)

Joseph A Lewnard, Nathan C Lo

[Targeting COVID-19 interventions towards migrants in humanitarian settings](#)

Sally Hargreaves, Dominik Zenner, Kolitha Wickramage, Anna Deal, Sally E Hayward

[COVID-19 and the coming epidemic in US immigration detention centres](#)

Jaimie P Meyer, Carlos Franco-Paredes, Parveen Parmar, Faiza Yasin, Matthew Gartland

Articles

[Estimates of the severity of coronavirus disease 2019: a model-based analysis](#)

Robert Verity, et al

Open Access

[Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in adults in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial](#)

Milagritos D Tapia, et al on behalf of the Zaire EBola Research Alliance group

[Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in children in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial](#)

Milagritos D Tapia, et al on behalf of the Zaire EBola Research Alliance group

Personal View

[Measles eradication—retreating is not an option](#)

David N Durrheim

Lancet Public Health

Jun 2020 Volume 5 Number 6 e297-e360

<https://www.thelancet.com/journals/lanpub/issue/current>

[New issue; No digest content identified]

Lancet Respiratory Medicine

May 2020 Volume 8 Number 5 p423-526, e27-e42

<http://www.thelancet.com/journals/lanres/issue/current>

[Reviewed earlier]

Maternal and Child Health Journal

Volume 24, Issue 6, June 2020

<https://link.springer.com/journal/10995/24/6>

Original Paper

[Integrated Family Planning and Routine Child Immunization Services in Benin: A Process Evaluation](#)

Blake Erhardt-Ohren, Heidi Schroffel, Roger Rochat

Medical Decision Making (MDM)

Volume 40 Issue 3, April 2020

<http://mdm.sagepub.com/content/current>

[Reviewed earlier]

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy

Volume 98, Issue 1 Pages: 1-222 March 2020

<https://onlinelibrary.wiley.com/toc/14680009/current>

[Reviewed earlier]

Nature

Volume 582 Issue 7810, 4 June 2020

http://www.nature.com/nature/current_issue.html

Focal Point | 03 June 2020

[Focal Point on Genomic Medicine in Thailand](#)

In 2019, the Thai government launched the Genomics Thailand Initiative to sequence the genomes of 50,000 Thai people and build infrastructure to harness genomic information.

Nature Biotechnology

Volume 38 Issue 5, May 2020

<https://www.nature.com/nbt/volumes/38/issues/5>

[Reviewed earlier]

Nature Communications

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 6 June 2020)

[No new digest content identified]

Nature Genetics

Volume 52 Issue 6, June 2020

<https://www.nature.com/ng/volumes/52/issues/6>

Editorial | 05 June 2020

Going virtual

One of the many consequences of the global COVID-19 pandemic is the need for the scientific community to adapt to the cancellation of conferences and events because of travel restrictions and social-distancing guidelines. We have seen a very swift conversion to online meetings, which have allowed for this established form of science communication to continue and opened new avenues for innovation in the reporting of research and discussion of ideas.

Nature Medicine

Volume 26 Issue 5, May 2020

<https://www.nature.com/nm/volumes/26/issues/5>

[Reviewed earlier]

Nature Reviews Genetics

Volume 21 Issue 6, June 2020

<https://www.nature.com/nrg/volumes/21/issues/6>

Editorial | 15 April 2020

Better together

Just as humans thrive from being part of a community, genetics and genomics benefit from interdisciplinary collaboration and knowledge integration.

Research Highlight | 08 April 2020

Diverse human genomes

A study in *Science* shows that anthropologically informed approaches to genome sequencing can provide a fuller understanding of human genetic variation, including new insights into how past events have led to present-day population structure.

Dorothy Clyde

Review Article | 14 February 2020

A systems approach to infectious disease

This Review outlines a broad, universal framework for systems biology applied to infectious disease research. From study design and omics data collection, analysis, visualization and interpretation to translational outcomes, the authors illustrate how systems biology can provide insights into host-pathogen relationships for the betterment of human health.

Manon Eckhardt

, Judd F. Hultquist[...] & Nevan J. Krogan

Review Article | 03 March 2020

Beyond broad strokes: sociocultural insights from the study of ancient genomes

With the increasing availability of ancient genomes from the same region or locality, the field of human history has started to address sociocultural aspects of human behaviour. The authors review recent case studies reconstructing the social consequences of past human migrations and advocate that this complex enterprise should be addressed by multidisciplinary teams.

Fernando Racimo, Martin Sikora[...] & Carles Lalueza-Fox

Perspective | 06 April 2020

Rights, interests and expectations: Indigenous perspectives on unrestricted access to genomic data

In this Perspective article, the authors discuss how Indigenous Peoples' desires for greater involvement and oversight when participating in genomic research projects can be balanced against calls for unrestricted data access. They provide practical recommendations for the handling and sharing of Indigenous genomic data, with the aim of achieving mutual benefit for the research community and participating Indigenous communities.

Maui Hudson, Nanibaa' A. Garrison [...] & Stephanie Russo Carroll

Nature Reviews Immunology

Volume 20 Issue 6, June 2020

<https://www.nature.com/nri/volumes/20/issues/6>

Comment | 11 May 2020

BCG-induced trained immunity: can it offer protection against COVID-19?

Could the BCG vaccine be used to bridge the gap until a specific COVID-19 vaccine is developed? Luke O'Neill and Mihai Netea discuss the science behind this approach.

Luke A. J. O'Neill & Mihai G. Netea

Comment | 28 April 2020

COVID-19 vaccine design: the Janus face of immune enhancement

Here, Hotez and colleagues highlight the two 'faces' of immune enhancement that could impact COVID-19 vaccine design.

Peter J. Hotez, David B. Corry & Maria Elena Bottazzi

Review Article | 28 April 2020

The trinity of COVID-19: immunity, inflammation and intervention

In the short time since SARS-CoV-2 infections emerged in humans, much has been learned about the immunological processes that underlie the clinical manifestation of COVID-19. Here, the authors provide an overview of the pathophysiology of SARS-CoV-2 infection and discuss potential therapeutic approaches.

Matthew Zirui Tay, Chek Meng Poh [...]

& Lisa F. P. Ng

Review Article | 04 March 2020

Defining trained immunity and its role in health and disease

Here a group of leaders in the field define our current understanding of 'trained immunity', which refers to the memory-type responses that occur in the innate immune system. The authors discuss our current understanding of the key epigenetic and metabolic processes involved in trained immunity and consider its relevance in immune-mediated diseases and cancer.

Mihai G. Netea, Jorge Domínguez-Andrés [...] & Eicke Latz

Nature Reviews Drug Discovery

Volume 19 Issue 6, June 2020

<https://www.nature.com/nrd/volumes/19/issues/6>

Comment | 11 November 2019

Cloud-based data systems in drug regulation: an industry perspective

Cloud-based systems for data submitted by sponsors to drug regulatory agencies have the potential to accelerate drug development, streamline regulatory review and enhance regulatory decision-making. Here, we provide a vision for integrating cloud-enabled practices in drug regulation globally.

Andrew S. Robertson, Hilary Malone [...] & Max Wegner

New England Journal of Medicine

June 4, 2020 Vol. 382 No. 23

<http://www.nejm.org/toc/nejm/medical-journal>

Perspective

Ensuring and Sustaining a Pandemic Workforce *E.P. Fraher and Others*

Covid-19 and Health Care's Digital Revolution *S. Keesara, A. Jonas, and K. Schulman*

Pediatrics

Jun 2020, 145 (6)

<https://pediatrics.aappublications.org/>

Pediatrics Perspectives

A Call to Action: Strengthening Vaccine Confidence in the United States

Sarah Mbaeyi, Amanda Cohn, Nancy Messonnier

Pharmaceutics

Volume 12, Issue 5 (May 2020)

<https://www.mdpi.com/1999-4923/12/4>

[New issue; No digest content identified]

PharmacoEconomics

Volume 38, Issue 5, May 2020

<https://link.springer.com/journal/40273/38/5>

[Reviewed earlier]

PLoS Genetics

<https://journals.plos.org/plosgenetics/>

(Accessed 6 June 2020)

[No new digest content identified]

PLoS Medicine

<http://www.plosmedicine.org/>

(Accessed 6 June 2020)

[No new digest content identified]

PLoS Neglected Tropical Diseases

<http://www.plosntds.org/>

(Accessed 6 June 2020)

[No new digest content identified]

PLoS One

<http://www.plosone.org/>

[Accessed 6 June 2020]

[Cost-effectiveness evaluations of the 9-Valent human papillomavirus \(HPV\) vaccine: Evidence from a systematic review](#)

Rashidul Alam Mahumud, Khorshed Alam, Syed Afroz Keramat, Gail M. Ormsby, Jeff Dunn, Jeff Gow

Research Article | published 02 Jun 2020 PLOS ONE

<https://doi.org/10.1371/journal.pone.0233499>

PLoS Pathogens

<http://journals.plos.org/plospathogens/>

[Accessed 6 June 2020]

[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States of America

<http://www.pnas.org/content/early/>

[Accessed 6 June 2020]

[Opinion: Intercepting pandemics through genomics](#)

Front Matter

W. John Kress, Jonna A. K. Mazet, and Paul D. N. Hebert

PNAS first published June 3, 2020. <https://doi.org/10.1073/pnas.2009508117>

Ecological interactions that cross domains of life have major impacts on ecosystems and human health. Although the coronavirus disease 2019 (COVID-19) pandemic makes this point with destructive clarity, it is clear that zoonotic pathogens pose a standing threat to our species as demonstrated by Ebola, Middle East respiratory syndrome (MERS), and severe acute respiratory syndrome (SARS). Other species experience similar pandemics and are both sources of, and sensitive to, shared pathogens.

Hence, there is an urgent need to establish a global, genomic-based biosurveillance platform, a development which would be of immense value to biosecurity, biodefense, and the economy. If implemented, this “pandemic interception system” would hugely advance our understanding of the natural world...

Prehospital & Disaster Medicine

Volume 35 - Issue 3 - June 2020

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

Preventive Medicine

Volume 135 June 2020

<https://www.sciencedirect.com/journal/preventive-medicine/vol/135/suppl/C>

[New issue; No digest content identified]

Proceedings of the Royal Society B

10 June 2020 Volume 287 Issue 1928

<https://royalsocietypublishing.org/toc/rspb/current>

[No new digest content identified]

Public Health

Volume 182 Pages 1-198 (May 2020)

<https://www.sciencedirect.com/journal/public-health/vol/182/suppl/C>

[Reviewed earlier]

Public Health Ethics

Volume 12, Issue 3, November 2019

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

Public Health Reports

Volume 135 Issue 3, May/June 2020

<https://journals.sagepub.com/toc/phrg/135/3>

[Reviewed earlier]

Qualitative Health Research

Volume 30 Issue 7, June 2020

<http://qhr.sagepub.com/content/current>

[New issue; No digest content identified]

Research Ethics

Volume 16 Issue 1-2, January-April 2020

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

Reproductive Health

<http://www.reproductive-health-journal.com/content>

[Accessed 6 June 2020]

[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

<https://www.paho.org/journal/en>

[No new digest content identified]

Risk Analysis

Volume 40, Issue 5 Pages: 899-1110 May 2020

<https://onlinelibrary.wiley.com/toc/15396924/current>

[Reviewed earlier]

Risk Management and Healthcare Policy

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 6 June 2020]

Rapid Communication

Spatial Analysis of Global Variability in Covid-19 Burden

Miller LE, Bhattacharyya R, Miller AL

Risk Management and Healthcare Policy 2020, 13:519-522

Published Date: 4 June 2020

Science

05 June 2020 Vol 368, Issue 6495

<http://www.sciencemag.org/current.dtl>

Editorial

Patents, economics, and pandemics

By Will Zerhouni, Gary J. Nabel, Elias Zerhouni

Science05 Jun 2020 : 1035

As coronavirus disease 2019 (COVID-19) has quickly killed hundreds of thousands across an unprepared world, destroyed the livelihoods of millions, and cost trillions of dollars, nations must now expand their mindsets and focus not only on overcoming the next phases but also on long-range strategies—for this and for future pandemics. The world needs a permanent preparedness enterprise to engage in a sustained effort to avert pandemics, and provide for the affordable and widespread administration of vaccines and therapies when they are discovered.

Governments, academia, and industry tend to forget the threat of infectious diseases between pandemics, but when they emerge, multibillion-dollar crash programs are quickly put into place. This boom-and-bust cycle in infectious diseases research and development (R&D) has limited attractiveness to scientists, thus preventing real progress. COVID-19 has mobilized the scientific community to generate hundreds of drugs, diagnostics, and vaccines in various stages of development, but this enthusiasm will quickly evaporate once the crisis is over and funding dries up. Existing governmental and market mechanisms fail to protect society against present and future public health threats, leading to chronic underinvestment in infectious diseases in the private sector and causing many companies to quietly abandon the field. Nonprofit

organizations try to fill the gap but are unlikely to meet public health needs. Without sustained government effort and investment, the world will be unprepared for pandemics.

Another reason for the market failure in pandemic protection is an inherent misalignment between economic incentives driving industry versus benefits to the public. Private innovation is driven by the patent system. Pharmaceutical companies, responsive to their shareholders, typically invest in therapies for conditions that will predictably maximize profits during the life of a patent. Patents give a time-limited exclusivity to the innovator who can then set premium pricing that maximizes the return on R&D investment. Such pricing can hinder wide dissemination once vaccines or therapies are developed, often leaving many patients unable to afford these products. Tension therefore exists between the need to generate affordable products that preserve human health and the need of innovators to be appropriately rewarded for their risk taking. This is more critical for vaccines as the individual vaccinee is not the only beneficiary. Indirect positive externalities accrue to the whole of society through faster herd immunity and more rapid economic recovery. In economic terms, this means that such products should be priced as close as possible to marginal costs, a proposition normally unattractive to drug innovators.

How is it possible to resolve this dilemma? A system of ex ante economic rewards should be created based on specific innovation and product development milestones. Governments should contribute not only emergency grant awards (which suffer from the need to pick winners and losers prospectively with scant evidence of effectiveness) but also sustained, predictable, and prospective achievement rewards or even prizes based on the value of explicitly achieved preclinical, clinical, manufacturing, and distribution milestones, including advanced market commitments when necessary to lessen the risk for the innovators who deliver. In exchange, prior to public funds being granted—and to avoid conflicts later—companies that accept taxpayer support would agree to make pandemic countermeasures available to the public rapidly, including widespread production and dissemination with reasonable margins. Today, industry practices such a system of milestone-based payments with their smaller R&D partners. Why should governments not do the same with industry for pandemics?

Similar proposals have been advanced in Europe, with the potential to license discoveries internationally. COVID-19 affects all of humanity, and the strategy should not be geographically restricted but global. Why not join forces? At the upcoming G7 and G20 meetings, governments should create and fund an international organization akin to a global institute of health to manage staged funding through calls for proposals from all sectors. This would sustain the R&D needed to establish rapidly scalable platforms and supply chains of diagnostics, drugs, antibodies, and vaccines against current and future pandemic threats. In exchange, innovators would be fairly rewarded, and their discoveries made available at affordable prices to people around the world. Creating such a sustainable R&D enterprise would be something positive to emerge from the wreckage of COVID-19.

⁴* Employee and shareholder of Sanofi (active in COVID-19 R&D). The views expressed here reflect my personal opinion and are independent of policies/positions of this organization.

⁵t Board member and shareholder of Danaher and shareholder of Sanofi (both involved in COVID-19 R&D).

Which interventions work best in a pandemic?

By Johannes Haushofer, C. Jessica E. Metcalf

Science05 Jun 2020 : 1063-1065 Full Access

Summary

The only approaches currently available to reduce transmission of the novel coronavirus severe acute respiratory syndrome–coronavirus 2 (SARS-CoV-2) are behavioral: handwashing, cough and sneeze etiquette, and, above all, social distancing. Policy-makers have a variety of tools to enable these “nonpharmaceutical interventions” (NPIs), ranging from simple encouragement and recommendations to full-on regulation and sanctions. However, these interventions are often used without rigorous empirical evidence: They make sense in theory, and mathematical models can be used to predict their likely impact (1, 2), but with different policies being tried in different places—often in complicated combinations and without systematic, built-in evaluation—we cannot confidently attribute any given reduction in transmission to a specific policy.

Science Translational Medicine

03 June 2020 Vol 12, Issue 546

<https://stm.sciencemag.org/>

Perspective

COVID-19 diagnostics in context

By Ralph Weissleder, Hakho Lee, Jina Ko, Mikael J. Pittet

Science Translational Medicine03 Jun 2020 Full Access

Abstract

The coronavirus disease 2019 (COVID-19) pandemic has highlighted the need for different types of diagnostics, comparative validation of new tests, faster approval by federal agencies, and rapid production of test kits to meet global demands. In this Perspective, we discuss the utility and challenges of current diagnostics for COVID-19.

Social Science & Medicine

Volume 252 May 2020

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/251/suppl/C>

[New issue; No digest content identified]

Systematic Reviews

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 6 June 2020]

[No digest content identified]

Travel Medicine and Infectious Diseases

Volume 34 March–April 2020

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/34/suppl/C>

[Reviewed earlier]

Tropical Medicine & International Health

Volume 25, Issue 6 Pages: i-iv, 645-750 June 2020

<https://onlinelibrary.wiley.com/toc/13653156/current>

[New issue; No digest content identified]

Vaccine

Volume 38, Issue 25 Pages 4057-4134 (22 May 2020)

<https://www.sciencedirect.com/journal/vaccine/vol/38/issue/25>

Short communication Full text access

[An opportunity to incentivize innovation to increase vaccine safety in the United States by improving vaccine delivery using vaccine patches](#)

Kimberly M. Thompson, Walter A. Orenstein, Alan R. Hinman

Research article Abstract only

[Trends in school-level vaccination coverage from 2015 to 2018: Increases in exemption rates and declines in herd immunity in Arizona](#)

Pooja Sangha, J. Mac McCullough

Research article Abstract only

[Case reduction and cost-effectiveness of the RTS,S/AS01 malaria vaccine alongside bed nets in Lilongwe, Malawi](#)

Griffin J. Bell, Matthew Loop, Hillary M. Topazian, Michael Hudgens, ... Michael Emch

Research article Abstract only

[Socioeconomic inequality trends in childhood vaccination coverage in India: Findings from multiple rounds of National Family Health Survey](#)

Nizamuddin Khan, Niranjan Saggurti

Research article Open access

[Validation of the new Swedish vaccination register – Accuracy and completeness of register data](#)

Cecilia Chrapkowska, Ilias Galanis, Malin Kark, Tiiia Lepp, ... Anna Nilsson

Research article Abstract only

[Regional variation in human papillomavirus vaccination uptake and completion among adolescents 13–17 in the state of Texas](#)

Reghan Conrey, Victoria Valencia, Anne Cioletti, M. Yvette Williams-Brown

Research article Abstract only

[HPV vaccine uptake among daughters of Latinx immigrant mothers: Findings from a cluster randomized controlled trial of a community-based, culturally relevant intervention](#)

Isabel C. Scarinci, Barbara Hansen, Young-il Kim

Vaccines — Open Access Journal

<http://www.mdpi.com/journal/vaccines>

(Accessed 6 June 2020)

Open Access Article

Socioeconomic Determinants in Vaccine Hesitancy and Vaccine Refusal in Italy

by Chiara Bertoncello , Antonio Ferro , Marco Fonzo , Sofia Zanovello , Giuseppina Napoletano , Francesca Russo , Vincenzo Baldo and Silvia Cocchio

Vaccines 2020, 8(2), 276; <https://doi.org/10.3390/vaccines8020276> (registering DOI) - 05 Jun 2020

Abstract

Childhood vaccination has been a milestone in the control of infectious diseases. However, even in countries offering equal access to vaccination, a number of vaccine-preventable diseases have re-emerged. Suboptimal vaccination coverage has been called into question. The aim was to explore socioeconomic inequalities [...]

Value in Health

May 2020 Volume 23, Issue 5, p527-676

[https://www.valueinhealthjournal.com/issue/S1098-3015\(20\)X0006-4](https://www.valueinhealthjournal.com/issue/S1098-3015(20)X0006-4)

THEMED SECTION: PRECISION MEDICINE

[Reviewed earlier]

* * * *

From Google Scholar & other sources: Selected Journal Articles, Newsletters, Dissertations, Theses, Commentary

No new digest content identified.

* * * *

Media/Policy Watch

This watch section is intended to alert readers to substantive news, analysis and opinion from the general media and selected think tanks and similar organizations on vaccines, immunization, global public health and related themes. *Media Watch* is not intended to be exhaustive, but indicative of themes and issues CVEP is actively tracking. This section will grow from an initial base of newspapers, magazines and blog sources, and is segregated from *Journal Watch* above which scans the peer-reviewed journal ecology.

We acknowledge the Western/Northern bias in this initial selection of titles and invite suggestions for expanded coverage. We are conservative in our outlook in adding news sources which largely report on primary content we are already covering above. Many electronic media sources have tiered, fee-based subscription models for access. We will provide full-text where content is published without restriction, but most publications require registration and some subscription level.

The Atlantic

<http://www.theatlantic.com/magazine/>
Accessed 6 June 2020
[No new, unique, relevant content]

BBC
<http://www.bbc.co.uk/>
Accessed 6 June 2020
[No new, unique, relevant content]

The Economist
<http://www.economist.com/>
Accessed 6 June 2020
The world after covid-19

Jennifer Doudna on how covid-19 is spurring science to accelerate
A change is under way in the respect for scientists, dissemination of research and forms of collaboration
Jun 5th 2020... More than 150 therapeutic or vaccine candidates are now in clinical trials and hundreds more are in pre-clinical development...

Schumpeter
The quest for a vaccine could restore faith in big pharma
The boffins of AstraZeneca are showing the way forward
Jun 5th 2020... Until the coronavirus, the company barely dabbled in the \$60bn-a-year vaccine business. Yet now he is leading the effort not just to create a ...

Financial Times
<http://www.ft.com/home/uk>
Accessed 6 June 2020
[No new, unique, relevant content]

Forbes
<http://www.forbes.com/>
Accessed 6 June 2020
Breaking /
Jun 5, 2020
Trump Says U.S. Is 'Ready To Go' With 2 Million Coronavirus Vaccines Upon Approval

No vaccine candidate has been approved, but companies have already begun ramping up for production.
By [Carlie Porterfield](#) Forbes Staff

Foreign Affairs
<http://www.foreignaffairs.com/>
Accessed 6 June 2020
Snapshot June 5, 2020
How to Keep the United States in the WHO
If carried out, withdrawing from the WHO would mark one of the most ruinous presidential decisions of modern history—a blow to global health security and to the rule of...

Harold Hongju Koh and Lawrence O. Gostin

Foreign Policy

<http://foreignpolicy.com/>

Accessed 6 June 2020 | [No new, unique, relevant content]
[No new, unique, relevant content]

The Guardian

<http://www.guardiannews.com/>

[No new, unique, relevant content]

New Yorker

<http://www.newyorker.com/>

Accessed 6 June 2020
[No new, unique, relevant content]

New York Times

<http://www.nytimes.com/>

Accessed 6 June 2020

Middle East

G20 Pledges More Than \$21 Billion to Fight Coronavirus

The Group of 20 rich and emerging economies has pledged more than \$21 billion to fight the coronavirus, the group said early on Saturday.

By Reuters June 5

Asia Pacific

Japan Aims to Have Coronavirus Vaccines in Use by June 2021

Japan aims to put coronavirus vaccines into use by June 2021, the health minister said on Friday, as the country strives to be fully ready to host the Tokyo Olympics, originally planned for this summer but postponed by one year due to the pandemic.

By Reuters June 5

Asia Pacific

Australia's CSL Says to Help Fund, Make Vaccine Candidate if It Proves Successful

Australia's biggest biotech firm CSL Ltd said it would help fund the development of a University of Queensland COVID-19 vaccine candidate and if it was successful, could make up to one hundred million doses towards the end of next year.

By Reuters June 4

Europe

AstraZeneca Targets Two Billion Doses, Poor Countries With COVID Vaccine Deals

British drugmaker AstraZeneca has doubled manufacturing capacity for its potential coronavirus vaccine to 2 billion doses in two deals involving Microsoft billionaire Bill Gates that guarantee early supply to lower income countries.

By Reuters

Washington Post

<https://www.washingtonpost.com/>

Accessed 6 June 2020

The biggest challenge for a coronavirus vaccine could be getting countries to share

William Wan and Carolyn Y. Johnson · Health · Jun 4, 2020

* * * *

Think Tanks et al

Brookings

<http://www.brookings.edu/>

Accessed 6 June 2020

Future Development

Developing countries can respond to COVID-19 in ways that are swift, at scale, and successful

Larry Cooley and Johannes F. Linn

Thursday, June 4, 2020

Center for Global Development [to 6 June 2020]

<http://www.cgdev.org/page/press-center>

Accessed 6 June 2020

India's COVID-19 Testing Capacity Must Grow by a Factor of 10: Here's How That Can Happen

Publication

6/4/20

Diagnostic testing is at the center of the policy debate around COVID-19 interventions in India. As of June 1, 2020, India had conducted approximately 3.8 million tests since it began testing in February, but many experts have noted that testing capacity is still drastically insufficient for the needs of the population.

Chatham House [to 6 June 2020]

<https://www.chathamhouse.org/>

Expert Comment

Equity, Trust and Accountability Vital in Preventing Pandemics

2 June 2020

COVID-19 has highlighted the common systemic weaknesses that have hindered the pandemic response in many countries, regardless of wealth or location.

Dr Mishal Khan. One Health Consultant, Global Health Programme

CSIS

<https://www.csis.org/>

Accessed 6 June 2020

Critical Questions

Strengthening Routine Immunizations and Responding to Covid-19

June 3, 2020 | By Katherine Bliss

Council on Foreign Relations

<http://www.cfr.org/>

Accessed 6 June 2020

[No new relevant content]

Kaiser Family Foundation

https://www.kff.org/search/?post_type=press-release

Accessed 6 June 2020

[No new relevant content]

* * * *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP)/GE2P2 Global, which is solely responsible for its content, and is an open access publication, subject to the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by-nc/3.0/>). Copyright is retained by CVEP.

CVEP is a program of the GE2P2 Global Foundation – whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances. CVEP maintains an academic affiliation with the Division of Medical Ethics, NYU School of Medicine, and an operating affiliation with the Vaccine Education Center of Children's Hospital of Philadelphia [CHOP].

Support for this service is provided by the Bill & Melinda Gates Foundation; PATH, and industry resource members Janssen/J&J, Pfizer, Sanofi Pasteur U.S., Takeda, Moderna Therapeutics (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

* * * *